Clinical Trial News and Research

RSS

Clinical trial initiated to determine feasibility, safety of focused ultrasound to treat depression

The first patient with depression has been treated with focused ultrasound. This procedure marks the beginning of a pilot clinical trial to determine the feasibility and safety of MR-guided focused ultrasound to non-invasively destroy a small volume of tissue deep in the brain - the anterior limb of the internal capsule - a well-established target for treating severe depression.

29 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

SLU biostatistician encourages people to interpret scientific and medical research

Thanks to the internet, access to research studies, medical news and health websites is greater than ever, offering instant admission to the world of medical knowledge.

29 Sep 2015

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc.

29 Sep 2015

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

29 Sep 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

28 Sep 2015

Two-drug combination relieves depression in older adults

More than half of older adults with clinical depression don't get better when treated with an antidepressant. But results from a multicenter clinical trial that included Washington University School of Medicine in St. Louis indicates that adding a second drug — an antipsychotic medication — to the treatment regimen helps many of those patients.

28 Sep 2015

Multigene test performed on tumor can identify breast cancer patients who can safely avoid chemotherapy

A major study published in the New England Journal of Medicine is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.

28 Sep 2015

Light-shielded delivery system for parenteral nutrition may improve survival rate of preemies

The survival rate of preemies born between 26 to 31 weeks of gestation is improved by blocking light from reaching the intravenously-fed infused nutritious mixture they depend on for survival, researchers at CHU Sainte-Justine and the University of Montreal have revealed in a new study.

28 Sep 2015

Nivolumab drug improves survival for non-SQ NSCLC patients

Patients with a type of lung cancer called non-squamous non-small cell lung cancer (non-SQ NSCLC) have limited treatment options and a dismal prognosis once their disease has advanced and initial treatment with platinum-based chemotherapy has failed. Second-line treatment is usually with another chemotherapy drug, such as docetaxel or pemetrexed.

28 Sep 2015

Two-drug combination improves progression-free survival in patients with advanced melanoma

Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone. New results show that these patients also do better regardless of their age, stage of disease and whether or not they have a cancer-driving mutation in the BRAF gene.

28 Sep 2015

SLU participates in Phase III clinical trial to treat early-onset preeclampsia

Saint Louis University is participating in a Phase III clinical trial for a drug to treat early-onset preeclampsia in pregnant women that could increase the length of pregnancy, resulting in improved fetal outcomes and reduced infant mortality.

26 Sep 2015

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine.

26 Sep 2015

New project aims to develop web-based tool for women considering CPM

Rutgers Cancer Institute of New Jersey surgical oncologist Laurie J. Kirstein, MD, FACS, and Associate Director for Cancer Prevention, Control and Population Science Sharon L. Manne, PhD, have been awarded a $404,089 grant (R21CA187643) from the National Cancer Institute to explore the decision making process women with non-hereditary breast cancer undergo when considering the removal of a healthy breast.

26 Sep 2015

Scripps becomes first health care provider in San Diego County to implant Evera MRI SureScan ICD System

Scripps Health is the first health care provider in San Diego County to use the only implantable cardioverter defibrillator (ICD) device approved for use with magnetic resonance imaging (MRI) scans.

26 Sep 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer.

26 Sep 2015

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

26 Sep 2015

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours.

From Novo Nordisk 26 Sep 2015

Researchers develop new blood test to diagnose coeliac disease

Diagnosis of coeliac disease requires a tissue sample from the small intestine, which can be extremely unpleasant. Researchers at the Faculty of Medicine have developed a blood test which provides a rapid, painless answer.

25 Sep 2015

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Resverlogix Corp. announced today the commencement of an Orphan Disease Program specific for Complement Mediated Diseases. New data generated by Resverlogix has demonstrated that BET inhibition by apabetalone (RVX-208) has effects on multiple biological pathways that underlie disease pathology.

24 Sep 2015

Clinical Trial News and Research

Clinical trial initiated to determine feasibility, safety of focused ultrasound to treat depression

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

SLU biostatistician encourages people to interpret scientific and medical research

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

New drug works better than current treatments for advanced kidney cancer

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Two-drug combination relieves depression in older adults

Multigene test performed on tumor can identify breast cancer patients who can safely avoid chemotherapy

Light-shielded delivery system for parenteral nutrition may improve survival rate of preemies

Nivolumab drug improves survival for non-SQ NSCLC patients

Two-drug combination improves progression-free survival in patients with advanced melanoma

SLU participates in Phase III clinical trial to treat early-onset preeclampsia

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

New project aims to develop web-based tool for women considering CPM

Scripps becomes first health care provider in San Diego County to implant Evera MRI SureScan ICD System

Patients with advanced kidney cancer benefit from cabozantinib treatment

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Researchers develop new blood test to diagnose coeliac disease

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer